[PDF][PDF] Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the …
HS Hochster, LL Hart, RK Ramanathan… - Journal of Clinical …, 2008 - researchgate.net
HS Hochster, LL Hart, RK Ramanathan, BH Childs, JD Hainsworth, AL Cohn, L Wong…
Journal of Clinical Oncology, 2008•researchgate.netSafety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without
Bevacizumab As First-Line Treatment of Metastat Page 1 Safety and Efficacy of Oxaliplatin and
Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic
Colorectal Cancer: Results of the TREE Study Howard S. Hochster, Lowell L. Hart, Ramesh
K. Ramanathan, Barrett H. Childs, John D. Hainsworth, Allen L. Cohn, Lucas Wong, Louis
Fehrenbacher, Yousif Abubakr, M. Wasif Saif, Lee Schwartzberg, and Eric Hedrick From the …
Bevacizumab As First-Line Treatment of Metastat Page 1 Safety and Efficacy of Oxaliplatin and
Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic
Colorectal Cancer: Results of the TREE Study Howard S. Hochster, Lowell L. Hart, Ramesh
K. Ramanathan, Barrett H. Childs, John D. Hainsworth, Allen L. Cohn, Lucas Wong, Louis
Fehrenbacher, Yousif Abubakr, M. Wasif Saif, Lee Schwartzberg, and Eric Hedrick From the …
Purpose
To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine regimens, with or without bevacizumab, as first-line treatment for metastatic colorectal cancer (CRC).
researchgate.net